These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31570466)

  • 1. Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
    Guo JC; Lin CC; Lin CY; Hsieh MS; Kuo HY; Lien MY; Shao YY; Huang TC; Hsu CH
    Anticancer Res; 2019 Oct; 39(10):5675-5682. PubMed ID: 31570466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
    Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
    Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma.
    Fu X; Li T; Dai Y; Li J
    BMC Cancer; 2019 Jul; 19(1):721. PubMed ID: 31331297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
    Lu J; Du L; Lei X; Zhang Z
    Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil to lymphocyte ratio as prognostic indicator for patients with esophageal squamous cell cancer.
    Gao GD; Sun B; Wang XB; Wang SM
    Int J Biol Markers; 2017 Oct; 32(4):e409-e414. PubMed ID: 28799624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y
    Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Zhou XL; Li YQ; Zhu WG; Yu CH; Song YQ; Wang WW; He DC; Tao GZ; Tong YS
    Sci Rep; 2017 Feb; 7():42581. PubMed ID: 28195186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the neutrophil-to-lymphocyte ratio for overall and disease-free survival in patients with surgically treated esophageal squamous cell carcinoma.
    Jung J; Park SY; Park SJ; Park J
    Tumour Biol; 2016 Jun; 37(6):7149-54. PubMed ID: 26662960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of neutrophil-lymphocyte ratio in operable esophageal squamous cell carcinoma.
    Duan H; Zhang X; Wang FX; Cai MY; Ma GW; Yang H; Fu JH; Tan ZH; Meng YQ; Fu XY; Ma QL; Lin P
    World J Gastroenterol; 2015 May; 21(18):5591-7. PubMed ID: 25987784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
    Booka E; Kikuchi H; Haneda R; Soneda W; Kawata S; Murakami T; Matsumoto T; Hiramatsu Y; Takeuchi H
    Anticancer Res; 2022 Jun; 42(6):2977-2987. PubMed ID: 35641297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of sarcopenia and inflammatory indices synergy in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy.
    Xiao L; Liu Y; Zhang X; Nie X; Bai H; Lyu J; Li T
    BMC Cancer; 2024 Jul; 24(1):860. PubMed ID: 39026185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
    Ji WH; Jiang YH; Ji YL; Li B; Mao WM
    Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer.
    Xie X; Luo KJ; Hu Y; Wang JY; Chen J
    Dis Esophagus; 2016 Jan; 29(1):79-85. PubMed ID: 25410116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Survival and the value of adjuvant chemotherapy in esophageal squamous cell carcinoma patients with lymphatic metastasis].
    Qi Z; Wang YX; Yang Q; Li J; Yao JF; He M
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):628-633. PubMed ID: 28835088
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic value of neutrophil-to-lymphocyte ratio in peripheral blood and pathological tissue in patients with esophageal squamous cell carcinoma.
    Guo Q; Shao Z; Xu D; Fan L; Xiong H; Ding X; You C; Zhang L
    Medicine (Baltimore); 2020 Jul; 99(29):e21306. PubMed ID: 32702926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort.
    Makino T; Nakai S; Momose K; Yamashita K; Tanaka K; Miyata H; Yamamoto S; Motoori M; Kimura Y; Ushimaru Y; Hirao M; Matsuyama J; Akamaru Y; Kurokawa Y; Eguchi H; Doki Y
    Esophagus; 2024 Jul; 21(3):319-327. PubMed ID: 38717686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Kim JH; Ahn B; Hong SM; Jung HY; Kim DH; Choi KD; Ahn JY; Lee JH; Na HK; Kim JH; Kim YH; Kim HR; Lee HJ; Kim SB; Park SR
    Cancer Res Treat; 2022 Apr; 54(2):505-516. PubMed ID: 34176250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood cell count ratios are predictive biomarkers of clinical response and prognosis for non-surgical esophageal squamous cell carcinoma patients treated with radiotherapy.
    Zhi X; Jiang K; Shen Y; Su X; Wang K; Ma Y; Zhou L
    J Clin Lab Anal; 2020 Oct; 34(10):e23468. PubMed ID: 32681567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study.
    Yu Y; Wu T; Gan W; Liu C; Zhang R; Zheng J; Xiong J; Chen J; Li J
    Clin Transl Oncol; 2024 Sep; 26(9):2360-2368. PubMed ID: 38602642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study.
    Toyokawa T; Kubo N; Tamura T; Sakurai K; Amano R; Tanaka H; Muguruma K; Yashiro M; Hirakawa K; Ohira M
    BMC Cancer; 2016 Sep; 16(1):722. PubMed ID: 27599460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.